# Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT

> **NCT05146245** · PHASE4 · UNKNOWN · sponsor: **Erasmus Medical Center** · enrollment: 140 (estimated)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **OTHER:** Therapeutic Drug Monitoring
- **OTHER:** Risperidone plasma level

## Key facts

- **NCT ID:** NCT05146245
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2024-05
- **Final completion:** 2024-05
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2023-12-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05146245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05146245, "Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05146245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*